Core Viewpoint - Dong-E E-Jiao is investing 1.485 billion yuan to build a health consumer goods industrial park, supporting its "1238" development strategy aimed at enhancing its dual business model of pharmaceuticals and health consumer products [1][2][3] Group 1: Investment and Strategic Development - The company plans to invest 1.485 billion yuan, with 1.421 billion yuan allocated for fixed assets and 0.64 billion yuan for working capital, to establish a health consumer goods industrial park [2] - The project will focus on the production of health consumer products, including food and health supplements, and will include facilities for quality inspection, e-commerce sorting, and storage [2][3] - The construction site is located in the Economic Development Zone of Dong'e County, Shandong Province, covering an area of 406,800 square meters, with a planned construction period of approximately 22 months [2][3] Group 2: Financial Performance and Shareholder Returns - Dong-E E-Jiao has shown consistent growth in revenue and net profit from 2020 to 2024, with revenue increasing from 3.409 billion yuan in 2020 to 5.921 billion yuan in 2024, and net profit rising from 0.43 billion yuan to 1.557 billion yuan during the same period [4][5] - The company has maintained a high dividend payout ratio, distributing a total of 4.081 billion yuan in dividends over five years, which exceeds its net profit during that period [6][7] - In the first three quarters of 2025, the company reported revenue of 4.766 billion yuan and a net profit of 1.274 billion yuan, reflecting a year-on-year growth of 4.41% and 10.53%, respectively [5][6]

Core Viewpoint - Dong'e Ejiao is making a significant investment of 1.485 billion yuan to build a health consumer goods industrial park, which is a strategic move to adapt to the trend of younger consumers and the foodification of products in the ejiao industry [2][3]. Investment Details - The total investment of 1.485 billion yuan includes 1.421 billion yuan for fixed assets and 64 million yuan for working capital, indicating a focus on capacity construction for health consumer goods [2][3]. - This investment is the largest single investment in the health consumer sector in recent years, highlighting the company's commitment to scaling production capabilities [3]. Market Trends - The consumer base for ejiao is expanding from "middle-aged women" to "universal health," with younger consumers driving demand for ready-to-eat products [3][5]. - By 2025, ready-to-eat ejiao products are expected to account for over 60% of the market, with 62% of young users preferring "ready-to-eat" formats [3]. Capacity and Financial Position - The construction of the industrial park aims to address the current capacity limitations in health consumer goods, which have been a barrier to rapid market growth for new products [4]. - As of Q3 2025, the company has total assets of 12.749 billion yuan and a low debt ratio of 21.77%, providing a solid financial foundation for the investment [4]. Industry Context - The ejiao industry has undergone significant changes, moving from price wars to value return and from traditional nourishment to consumption upgrades [5][6]. - Dong'e Ejiao holds a dominant market share of 70% in the ejiao block category, indicating a strong competitive position [5]. Policy Support - The national push for high-quality development in traditional Chinese medicine provides a favorable environment for Dong'e Ejiao's expansion into health consumer goods [7]. Challenges Ahead - The construction of the industrial park will take 2-3 years, and the company must ensure that production capacity aligns with rapidly changing market demands [8]. - The health consumer goods sector is highly competitive, requiring innovative product development to meet the needs of younger consumers [8]. - The company needs to enhance its online sales channels and improve operational efficiency to compete effectively in the new retail landscape [8]. Industry Implications - Dong'e Ejiao's strategy serves as a reference for traditional Chinese medicine companies, emphasizing the need for product innovation and industry upgrades to achieve sustainable development [9].

Group 1 - The core point of the article is the decision made by the Board of Directors of Dong'e Ejiao Co., Ltd. to invest 1.485 billion yuan in the construction of a health consumer goods industrial park to support the high-quality development of its health consumer goods business [7][16][22] Group 2 - The Board of Directors meeting was held on February 9, 2026, with all 9 directors present, and the meeting complied with relevant laws and regulations [2][4][5] - The meeting approved several proposals, including adjustments to the members of the Board's specialized committees and the investment project for the health consumer goods industrial park [6][7][10] Group 3 - The investment project will utilize 1.485 billion yuan of the company's own funds, with 1.421 billion yuan allocated for fixed asset investment and 0.64 billion yuan for working capital [16][19] - The project aims to produce health consumer goods such as food and health supplements, and will include facilities for production, warehousing, quality inspection, and e-commerce [18][21] Group 4 - The construction of the industrial park is expected to take approximately 22 months from the start of construction [18] - The investment aligns with the company's "1238" development strategy, which focuses on high-quality development in traditional Chinese medicine and expanding into health consumer goods [21][22] Group 5 - The project is deemed necessary to meet the growing demand for health consumer products and to overcome current production capacity limitations [21][22] - The investment is expected to enhance the company's competitive advantage and support sustainable development without affecting existing business operations [22]

Core Viewpoint - Dong'e Ejiao has announced a significant investment of 1.485 billion yuan to build a health consumer goods industrial park in Shandong Province, marking one of its largest single investments in recent years and a key step in its "pharmaceutical + health consumer goods" dual-drive strategy [2][5]. Investment Details - The project will cover an area of 406,800 square meters, with a construction area of 151,100 square meters [6]. - Out of the total investment of 1.485 billion yuan, 1.421 billion yuan will be allocated to fixed asset investment, while 64 million yuan will be for working capital. The funding will come entirely from the company's own resources, with a construction period of 22 months [8]. Strategic Focus - The new industrial park aims to produce health consumer goods such as medicinal food, health supplements, and functional foods, including products like Ejiao cake, Ejiao dates, and Ejiao powder. It will also feature a comprehensive warehouse and e-commerce center, along with a quality inspection incubation center [8]. - The company has reported a revenue of 4.766 billion yuan for the first three quarters of 2025, a year-on-year increase of 4.41%, and a net profit of 1.274 billion yuan, up 10.53% year-on-year. As of the end of the third quarter of 2025, the company had cash reserves of 5.562 billion yuan [8]. Market Challenges - The company faces significant challenges related to the scarcity of its core raw material, donkey hide, which is crucial for its products. The decreasing availability of this resource poses a risk to the company's growth and expansion plans [9]. - To address this "raw material anxiety," the company is focusing on increasing the utilization and added value of its raw materials by extending into health consumer goods. This strategy includes developing deep-processed products that reduce reliance on single raw materials and enhance overall profit margins [10]. Competitive Landscape - The health consumer goods market is highly competitive, with many established players, making it more complex than the traditional pharmaceutical market where Dong'e Ejiao holds a dominant position. The company recognizes the importance of channel development and research, as indicated by the inclusion of an e-commerce center and a new product incubation center in the new park [10].

Core Viewpoint - China Resources Pharmaceutical (华润医药) announced that its non-wholly owned subsidiary, Dong'e Ejiao (东阿阿胶), has decided to invest in and construct a health consumer goods industrial park, which will enhance its production capabilities and support the growth of its health consumer goods business [1][2]. Group 1: Investment and Construction Details - The health consumer goods industrial park is expected to include manufacturing facilities for health consumer products (such as pharmaceuticals, health foods, and functional foods), along with supporting warehousing, logistics facilities, quality inspection centers, new product incubation centers, and e-commerce sorting and finished product warehouses [1]. - The total area of the health consumer goods industrial park is approximately 406,800 square meters, with a proposed construction area of 151,100 square meters, which will include production facilities for Ejiao cakes, Ejiao dates, and Ejiao powder, as well as comprehensive warehouses and other storage facilities [1]. - The total investment for the project is estimated to be around RMB 1.485 billion, with fixed asset investment amounting to approximately RMB 1.421 billion and working capital of about RMB 64 million [1]. Group 2: Strategic Importance - The investment and construction of the health consumer goods industrial park is a necessary requirement for Dong'e Ejiao to implement its "1238" strategy, aiming to create a model for high-quality development in traditional Chinese medicine [2]. - The project is designed to establish a dual-driven business growth model combining pharmaceuticals and health consumer goods, fostering a second growth curve while addressing the urgent needs for the development of health consumer goods [2]. - The existing industrial park faces limitations in expansion and capacity bottlenecks, which hinder the ability to meet the rapid upgrades and iterations in health consumer goods, making the new construction essential for maintaining competitive advantages [2].

Group 1 - The company Huaren Pharmaceutical (03320) announced that its non-wholly owned subsidiary Dong'e Ejiao (000423.SZ) has decided to invest in and construct a health consumer goods industrial park [1] - The health consumer goods industrial park is expected to include manufacturing facilities for health consumer products (such as pharmaceuticals, health foods, and functional foods), along with supporting warehousing and logistics facilities, quality inspection centers, new product incubation centers, and e-commerce sorting and finished product warehouses [1] - The total area of the health consumer goods industrial park is approximately 406,800 square meters, with a proposed construction area of 151,100 square meters, including production facilities for Ejiao cakes, Ejiao dates, and Ejiao powder, as well as comprehensive warehouses and other storage facilities [1] Group 2 - The investment and construction of the health consumer goods industrial park is a necessary requirement for Dong'e Ejiao to implement its "1238" strategy, aiming to create a model for high-quality development in traditional Chinese medicine and establish a dual-driven business growth model of pharmaceuticals and health consumer goods [2] - The existing industrial park of Dong'e Ejiao faces limitations in expansion area and capacity bottlenecks in major production lines, which cannot meet the rapid upgrading and iteration needs of health consumer products [2] - Building the new facilities will help Dong'e Ejiao establish a core advantage in the health consumer goods sector, with a focus on Ejiao series products, enhancing brand regional recognition, and strengthening core competitiveness [2]

Core Viewpoint - Dong'e Ejiao plans to repurchase A-shares with a total fund of between 100 million and 200 million yuan, marking the first share buyback and cancellation since its listing, aimed at enhancing investor confidence and recognizing the company's intrinsic value [1][2]. Group 1: Share Buyback Details - The repurchase price ceiling is set at 72.08 yuan per share, which is 150% of the average trading price over the previous 30 trading days [1]. - The estimated number of shares to be repurchased ranges from 1.3873 million to 2.7747 million, accounting for 0.22% to 0.43% of the current total share capital of 643,976,824 shares [1]. - The buyback period will last up to 12 months from the date of shareholder approval, with the board having the discretion to adjust the plan based on market conditions [1]. Group 2: Financial Position - As of September 30, 2025, Dong'e Ejiao's total assets are 12.749 billion yuan, with equity attributable to shareholders at 9.948 billion yuan and current assets at 9.823 billion yuan [2]. - The maximum repurchase amount of 200 million yuan represents only 1.57% of total assets, 2.01% of equity, and 2.04% of current assets, indicating a minimal impact on the company's financial health [2]. - The company asserts that the buyback will not significantly affect its daily operations, financial status, or future development [2]. Group 3: Business Performance and Strategy - Dong'e Ejiao reported a revenue of 4.766 billion yuan for the first three quarters of 2025, a year-on-year increase of 4.41%, with a net profit of 1.274 billion yuan, reflecting a growth of 10.53% [2]. - The company has maintained a high cash dividend policy, ranking first in the cash dividend payment rate among listed companies, with cumulative dividends exceeding 10 billion yuan since its listing [3]. - In 2025, Dong'e Ejiao made significant acquisitions, including a 70% stake in Ma Ji Pharmaceutical and an 80% stake in Alashan Corgoni Group, aiming to expand its product offerings in the male health supplement market [3].

Investment Rating - The investment rating for the company is "Buy" and it is maintained [4]. Core Views - The company reported a revenue of 4.766 billion yuan for the first nine months of 2025, representing a year-on-year growth of 4.41%. The net profit attributable to shareholders was 1.274 billion yuan, up 10.53% year-on-year [2][4]. - In Q3 2025, the company achieved a revenue of 1.716 billion yuan, reflecting an 8.50% year-on-year increase, with a net profit of 456 million yuan, which is a 10.27% increase year-on-year [2][4]. - The company is focusing on enhancing its overseas business layout and has made significant strides in brand value and product development [8]. Summary by Sections Financial Performance - For the first nine months of 2025, the company achieved a revenue of 47.66 billion yuan, a net profit of 12.74 billion yuan, and a non-recurring net profit of 11.55 billion yuan, with respective year-on-year growth rates of 4.41%, 10.53%, and 8.23% [2][4]. - In Q3 2025, the company reported a revenue of 17.16 billion yuan, a net profit of 4.56 billion yuan, and a non-recurring net profit of 3.68 billion yuan, with year-on-year growth rates of 8.50%, 10.27%, and 0.06% respectively [2][4]. Business Strategy - The company is implementing a "growth and breakthrough" management theme for 2025, focusing on quality improvements and deepening its core business in the traditional Chinese medicine sector [8]. - The company has been recognized for its brand value, ranking 16th in the "Top 500 Most Valuable Brands in China" with a brand value of 49.7 billion yuan, an 11% increase from 2024 [8]. - The company has successfully established key research and development centers and expanded its product offerings, including the inclusion of its compound Ejiao syrup in expert consensus for treating cancer-related anemia [8]. Profit Forecast - The company is expected to achieve net profits of 1.738 billion yuan, 1.968 billion yuan, and 2.214 billion yuan for the years 2025, 2026, and 2027 respectively, with corresponding earnings per share (EPS) of 2.70 yuan, 3.06 yuan, and 3.44 yuan [8].

Core Insights - The article emphasizes the significance of traditional Chinese brands, known as "Chinese Time-honored Brands," which embody the essence of Chinese culture and have evolved through innovation over centuries [1][2]. Group 1: Current Status of Chinese Time-honored Brands - The Ministry of Commerce has recognized a total of 1,450 Chinese Time-honored Brands [2]. - Recent events, such as the International Exchange Activity and the Fifth Innovation Development Conference, have brought together representatives from various brands to explore new paths for innovation and collaboration [2]. Group 2: Commitment to Craftsmanship - The enduring success of Time-honored Brands is attributed to their commitment to craftsmanship and cultural heritage, which are closely linked to the nation's economy and people's livelihoods [3]. - Brands like Liu Bi Ju and Tong Ren Tang exemplify this commitment through their dedication to quality and ethical practices [3]. - Dong'e Ejiao has maintained its unique production techniques for nearly 3,000 years, emphasizing the importance of preserving traditional methods while modernizing [3]. Group 3: Innovation and Market Adaptation - Time-honored Brands are actively adapting to market demands by embracing innovation, targeting younger consumers, and leveraging digital technologies [4][5]. - Dong'e Ejiao has successfully transformed its image from an "elderly brand" to a trendy national brand by collaborating with popular tea brands and launching products that appeal to younger audiences [5][6]. - China Tea Company has focused on optimizing product flavors and modernizing packaging to attract younger consumers [6]. Group 4: Digital Transformation - The digital transformation of Time-honored Brands is crucial for their evolution, with Dong'e Ejiao achieving a digitalization level that meets the highest standards [6]. - The online business of Dong'e Ejiao now accounts for nearly 30% of its overall operations, showcasing the impact of digital strategies [6]. - China Tea Company is implementing digital controls across the entire supply chain, from cultivation to processing [7]. Group 5: Cultural Export and Global Reach - Time-honored Brands are becoming important vehicles for cultural export, with Tong Ren Tang expanding its presence globally since the 1990s [7]. - Dong'e Ejiao has participated in international conferences to promote traditional Chinese medicine, indicating a growing acceptance of Chinese culture abroad [7]. - China Tea Company aims to share Chinese culture through tea, enhancing global consumer experiences with Chinese lifestyle and values [7].

Investment Rating - The report maintains an "Accumulate" rating for the company with a target price of 83.65 RMB [7][5]. Core Views - The company has shown resilient growth despite industry pressures, with revenue and net profit for the first three quarters of 2025 reaching 47.7 billion RMB and 12.7 billion RMB, respectively, reflecting year-on-year growth of 4% and 11% [1]. - The company is expected to continue its double-digit growth in the Ejiao series, driven by online channel expansion and consumer recovery [2]. - The company is accelerating its expansion in the tonic product category, with strategic partnerships in various product lines, aiming to transition from a leader in Ejiao to a leader in comprehensive tonics during the 14th Five-Year Plan period [3]. Financial Performance - The sales, management, and R&D expense ratios for the first three quarters of 2025 are 35.2%, 6.1%, and 3.0%, respectively, indicating a continuous optimization in sales expenses and an increase in R&D expenses due to strategic investments [4]. - The operating cash flow for the first three quarters of 2025 is 13.1 billion RMB, slightly higher than net profit, indicating strong cash flow management [4]. Earnings Forecast - The report projects net profits for 2025, 2026, and 2027 to be 18.0 billion RMB, 20.5 billion RMB, and 23.2 billion RMB, respectively, with year-on-year growth rates of 15%, 14%, and 13% [5][11].